Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Elias Jabbour, Hagop M. Kantarjian, Lynne V. Abruzzo, Susan O'Brien, Guillermo Garcia-Manero, Srdan Verstovsek, Jianqin Shan, Mary Beth Rios, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

The development of chromosomal abnormalities (CAs) in the Philadelphia chromosome(Ph)-negative metaphases during imatinib (IM) therapy in patients with newly diagnosed chronic myecloid leukemia (CML) has been reported only anecdotally. We assessed the frequency and significance of this phenomenon among 258 patients with newly diagnosed CML in chronic phase receiving IM. After a median follow-up of 37 months, 21 (9%) patients developed 23 CAs in Ph-negative cells; excluding -Y, this incidence was 5%. Sixteen (70%) of all CAs were observed in 2 or more metaphases. The median time from start of IM to the appearance of CAs was 18 months. The most common CAs were -Y and +8 in 9 and 3 patients, respectively. CAs were less frequent in young patients (P = .02) and those treated with high-dose IM (P = .03). In all but 3 patients, CAs were transient and disappeared after a median of 5 months. One patient developed acute myeloid leukemia (associated with - 7). At last follow-up, 3 patients died from transplantation-related complications, myocardial infarction, and progressive disease and 2 lost cytogenetic response. CAs occur in Ph-negative cells in a small percentage of patients with newly diagnosed CML treated with IM. In rare instances, these could reflect the emergence of a new malignant clone.

Original languageEnglish (US)
Pages (from-to)2991-2995
Number of pages5
JournalBlood
Volume110
Issue number8
DOIs
StatePublished - Oct 15 2007

Fingerprint

Leukemia, Myeloid, Chronic Phase
Philadelphia Chromosome
Metaphase
Chromosomes
Chromosome Aberrations
Leukemia
Therapeutics
Imatinib Mesylate
Acute Myeloid Leukemia
Cytogenetics
Clone Cells
Transplantation
Myocardial Infarction

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. / Jabbour, Elias; Kantarjian, Hagop M.; Abruzzo, Lynne V.; O'Brien, Susan; Garcia-Manero, Guillermo; Verstovsek, Srdan; Shan, Jianqin; Rios, Mary Beth; Cortes, Jorge.

In: Blood, Vol. 110, No. 8, 15.10.2007, p. 2991-2995.

Research output: Contribution to journalArticle

Jabbour, Elias ; Kantarjian, Hagop M. ; Abruzzo, Lynne V. ; O'Brien, Susan ; Garcia-Manero, Guillermo ; Verstovsek, Srdan ; Shan, Jianqin ; Rios, Mary Beth ; Cortes, Jorge. / Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. In: Blood. 2007 ; Vol. 110, No. 8. pp. 2991-2995.
@article{25887997d3dd4e2f956bdf220cf1e322,
title = "Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase",
abstract = "The development of chromosomal abnormalities (CAs) in the Philadelphia chromosome(Ph)-negative metaphases during imatinib (IM) therapy in patients with newly diagnosed chronic myecloid leukemia (CML) has been reported only anecdotally. We assessed the frequency and significance of this phenomenon among 258 patients with newly diagnosed CML in chronic phase receiving IM. After a median follow-up of 37 months, 21 (9{\%}) patients developed 23 CAs in Ph-negative cells; excluding -Y, this incidence was 5{\%}. Sixteen (70{\%}) of all CAs were observed in 2 or more metaphases. The median time from start of IM to the appearance of CAs was 18 months. The most common CAs were -Y and +8 in 9 and 3 patients, respectively. CAs were less frequent in young patients (P = .02) and those treated with high-dose IM (P = .03). In all but 3 patients, CAs were transient and disappeared after a median of 5 months. One patient developed acute myeloid leukemia (associated with - 7). At last follow-up, 3 patients died from transplantation-related complications, myocardial infarction, and progressive disease and 2 lost cytogenetic response. CAs occur in Ph-negative cells in a small percentage of patients with newly diagnosed CML treated with IM. In rare instances, these could reflect the emergence of a new malignant clone.",
author = "Elias Jabbour and Kantarjian, {Hagop M.} and Abruzzo, {Lynne V.} and Susan O'Brien and Guillermo Garcia-Manero and Srdan Verstovsek and Jianqin Shan and Rios, {Mary Beth} and Jorge Cortes",
year = "2007",
month = "10",
day = "15",
doi = "10.1182/blood-2007-01-070045",
language = "English (US)",
volume = "110",
pages = "2991--2995",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase

AU - Jabbour, Elias

AU - Kantarjian, Hagop M.

AU - Abruzzo, Lynne V.

AU - O'Brien, Susan

AU - Garcia-Manero, Guillermo

AU - Verstovsek, Srdan

AU - Shan, Jianqin

AU - Rios, Mary Beth

AU - Cortes, Jorge

PY - 2007/10/15

Y1 - 2007/10/15

N2 - The development of chromosomal abnormalities (CAs) in the Philadelphia chromosome(Ph)-negative metaphases during imatinib (IM) therapy in patients with newly diagnosed chronic myecloid leukemia (CML) has been reported only anecdotally. We assessed the frequency and significance of this phenomenon among 258 patients with newly diagnosed CML in chronic phase receiving IM. After a median follow-up of 37 months, 21 (9%) patients developed 23 CAs in Ph-negative cells; excluding -Y, this incidence was 5%. Sixteen (70%) of all CAs were observed in 2 or more metaphases. The median time from start of IM to the appearance of CAs was 18 months. The most common CAs were -Y and +8 in 9 and 3 patients, respectively. CAs were less frequent in young patients (P = .02) and those treated with high-dose IM (P = .03). In all but 3 patients, CAs were transient and disappeared after a median of 5 months. One patient developed acute myeloid leukemia (associated with - 7). At last follow-up, 3 patients died from transplantation-related complications, myocardial infarction, and progressive disease and 2 lost cytogenetic response. CAs occur in Ph-negative cells in a small percentage of patients with newly diagnosed CML treated with IM. In rare instances, these could reflect the emergence of a new malignant clone.

AB - The development of chromosomal abnormalities (CAs) in the Philadelphia chromosome(Ph)-negative metaphases during imatinib (IM) therapy in patients with newly diagnosed chronic myecloid leukemia (CML) has been reported only anecdotally. We assessed the frequency and significance of this phenomenon among 258 patients with newly diagnosed CML in chronic phase receiving IM. After a median follow-up of 37 months, 21 (9%) patients developed 23 CAs in Ph-negative cells; excluding -Y, this incidence was 5%. Sixteen (70%) of all CAs were observed in 2 or more metaphases. The median time from start of IM to the appearance of CAs was 18 months. The most common CAs were -Y and +8 in 9 and 3 patients, respectively. CAs were less frequent in young patients (P = .02) and those treated with high-dose IM (P = .03). In all but 3 patients, CAs were transient and disappeared after a median of 5 months. One patient developed acute myeloid leukemia (associated with - 7). At last follow-up, 3 patients died from transplantation-related complications, myocardial infarction, and progressive disease and 2 lost cytogenetic response. CAs occur in Ph-negative cells in a small percentage of patients with newly diagnosed CML treated with IM. In rare instances, these could reflect the emergence of a new malignant clone.

UR - http://www.scopus.com/inward/record.url?scp=35548971639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35548971639&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-01-070045

DO - 10.1182/blood-2007-01-070045

M3 - Article

C2 - 17625066

AN - SCOPUS:35548971639

VL - 110

SP - 2991

EP - 2995

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -